MINNETONKA ENTERING Rx MARKET WITH TRANSDERMAL WART REMOVAL

Executive Summary

MINNETONKA ENTERING Rx MARKET WITH TRANSDERMAL WART REMOVAL product, the firm's corporate VP Robert Hebeisen told the New York Society of Security Analysts on Dec. 4. Trademarked Tran-sal, the product consists of salicylic acid in a transdermal patch. Minnetonka plans to launch its first prescription product in March. The firm maintains that regulatory approval from FDA is not needed to market the product. Hebeisen said that in clinical tests Tran-sal was shown to be "highly effective" in treating warts and less irritating than the leading prescription wart removers. Minnetonka said it developed the product in collaboration with the dermatology department of a mid-western university. Tran-sal will be sold in kits containing 40 transdermal pads and adhesive tape at a suggested retail price of $18.50 per kit. Minnetonka's Davron professional skin care group will market the product. The division curently markets a variety of professional soaps and skin care items through 45 independent manufacturer representatives and several hospital supply distributors. Minnetonka said the division accounts for less than 5% of corporate sales. Minnetonka had 1985 sales of approximately $124 mil.